Disclaimer

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

There can be no assurance that any existing or future regulatory filings will satisfy any health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Any statements regarding earnings is not a profit forecast and should not be interpreted to mean that Medical Developments International’s earnings for this year or any subsequent period will necessarily match or exceed the historical published earnings of Medical Developments International. Medical Developments International Limited, its directors, officers and employees do not accept any liability whatsoever for any damage or loss caused by anything contained in this document.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com

All mentioned trademarks are legally protected.
Medical Developments International (MVP) is a leading Emergency Medicine Company.

Our aim is to:

1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader globally.

2. Provide unique and innovative products to assist our customers in the management of delivery of respiratory medications, resuscitation and oxygen therapies and to be the market leader in Medical Devices for Asthma and COPD markets globally.
Penthrox®
Penthrox®
UK and Ireland update

In market sales in the UK and Ireland grew 167% in H2FY17.
There are 56 hospital formulary approvals.
All 56 hospitals are ordering on a regular basis.
Penthrox has been sold into 122 Hospitals, clinics and ambulance services in the UK and Ireland so far.
Many of these first sales are “pre formulary” approvals.
20+ additional formulary approvals are expected in the next few months, including Kings College.
In market sales into hospitals are growing at a rate of 20+% a month for the last 6 months.
We are delighted by our partner’s progress in France.

In market sales in France are growing quickly. In summary:

• The target is 350 hospitals to approve Penthrox in France.
• 250 formulary applications have already been submitted.
• 99 formularies have approved Penthrox in France.
• 21 formularies have rejected the formulary applications.
• 143 hospitals have ordered Penthrox in France.
• About 50% of customers who have ordered Penthrox have already re-ordered.
Penthrox®

Regulatory approval for Penthrox in the rest of Europe

We are ahead of our timeline for Penthrox to be approved in another 22 European countries. Sales are expected during H2FY18.

We expect Regulatory Approvals for an additional 15 countries during 2018.

- Czech Republic
- Poland
- Slovenia
- Macedonia
- Albania
- Montenegro
- Kosovo
- Slovakia
- Croatia
- Serbia
- Greece
- Malta
- Norway
- Andorra
- Italy
- Germany
- Sweden
- Switzerland
- Mexico
- Portugal
- Spain
- Saudi Arabia
- Hong Kong
- Jordan
- Iraq
- Canada
- Austria
- South Korea
- Netherlands
- Denmark
- Luxembourg
- Liechtenstein
- Monaco
- San Marino
- Estonia
- Vatican City
- Herzegovina

Expected approvals for Penthrox® over the next 12 to 18 months
Sales of Penthrox to Ambulance in Australia remain strong.
Sales of Penthrox to Hospitals grew 20%.
Sales of Penthrox to GP’s grew 21%.
Sales of Penthrox to NZ Ambulance grew 593% as a result of all NZ Ambulances adopting Penthrox as first line sole analgesia in all ambulances.
Work on getting Penthrox approved in the USA is progressing well.

We are on track to submit our IND in the next six months.

After discussions with the FDA we will request Penthrox be granted “fast track” status by the FDA.

We are very encouraged by our recent FDA meeting.

We believe the aggressive negative bias against opioids for analgesia in the USA make Penthrox a compelling alternative.
Future of Penthrox®

Penthrox® clinical program for USA

2017

- IND Toxicology:
  - 2 by 28 Day Repeat Dose studies
  - General validation and assay studies to support existing data

- Safety Pharmacology:
  - General functional Observational Battery studies to support existing data

2018

- Repeat dose and dose ranging Healthy Volunteer Trial

- IND Pharmacokinetics:
  - General In Vitro studies to support existing data

- FDA meeting

2019

- Additional Phase III to support existing Phase III studies and data

- Phase III & NDA Pharmacokinetics and Toxicology Studies:
  - General studies to support existing data
  - Pre NDA meeting with FDA

- Submit NDA to US FDA

2020

- FDA Approval

- Launch In USA
Future of Penthrox®
Global growth plans

Pre 2000
- 1975 Launched: Australia
- 2002 Launched: New Zealand

2009
- 2009 Launched: Moldova

2010
- 2010 Launched: Azerbaijan, Georgia, Ukraine
- 2011 Launched: Guatemala

2011
- 2011 Launched: Kazakhstan

2014
- 2014 Launched: South Africa

2015
- 2015 Launched: Singapore
- 2016 Launched: Ireland, UAE, UK
- 2017 & 2018 Planned Launch: Canada, Germany, Italy, Spain, Switzerland, Portugal, Austria, South Korea, Netherlands, Denmark, Luxembourg, Czech Republic, Poland, Sweden, Slovakia, Macedonia, Albania, Montenegro, Kosovo, Hong Kong

2016
- 2016 Planned Launch: China

2017
- 2017 Planned Launch: France, Belgium, Mexico, Taiwan, Jordan, Iraq
- 2017 & 2018 Planned Launch: USA, Moldova

2018
- 2018 & 2019 Planned Launch: Slovenia, Croatia, Serbia, Greece, Malta, Norway, Hungary, Liechtenstein, Monaco, Saudi Arabia, San Marino, Bosnia, Vatican City, Herzegovina, Andorra

2019
- 2019-2020 Planned Launch: Brazil, Columbia, Chile, Argentina, Malaysia, Thailand, Philippines, Indonesia

2020
- 2020 Planned Launch: Russia

2021
- 2021 Planned Launch: China

2021 - 2022 Planned Launch: 
- USA
- Russia

Global growth plans

Medical Developments International
Additional clinical trials and studies are planned for FY18 (and beyond) which will broaden the indications for use of Penthrox®. Our longer term ambition is to extend the use of Penthrox® into:

- Acute Pain / Minor Surgical Procedures (market size estimate $2 billion);
- Acute Anxiety – replacement therapy for SSRI’s or Benzo’s;
- Breakthrough Pain / Repeat Use (market size estimate $6 billion); and ultimately
- Home Use / First aid box.
A summary of clinical trials and studies underway (including in planning stage) which are designed to gain regulatory approvals around the world and extend the approved “indications of use” for Penthrox:

- Paediatric study for Penthrox in Europe. This will be used to gather additional approvals around the world.
- Head to head study Penthrox v Standard of care in the ER (including opioids-Italy). Global application.
- Head to head study Penthrox v Standard of care in the ER (including opioids-Spain). Global application.
- Nurse Initiated Pain Protocol with Self-Administered Inhaled Analgesia in the Emergency Department (Sing Health).
- A Post Authorisation Safety Study for the users of Penthrox in Europe. Global application – particularly USA.
- Animal studies covering toxicity, repeat use and pharmacokinetics (USA).
- 2 x Healthy Volunteer studies (USA and Europe). Designed for USA approval and global indication extensions.
- Truss Biopsy in Australia (to promote use of Penthrox in minor surgical procedures).
- Penthrox in Acute Pain – colonoscopy (Europe). To extend the indication in Europe and elsewhere to Acute Pain Procedures.
Future of Penthrox®
New manufacturing technology

Our new manufacturing facility has been completed on time and on budget.

TGA is scheduled to return and audit the facility during September.

We expect to be fully GMP compliant by the end of 2017.

The new facility will deliver a quantum shift in the manufacturing of Penthrox in terms of cost, quality, consistence and capacity.
Our Process Development Project (PDP) with the CSIRO is progressing very well. Our ambition is to develop new manufacturing technologies that will deliver cost saving, improved quality, consistency and safety standards for existing and new small molecule pharmaceuticals.

We have successfully completed ‘desk top’ scientific due diligence on 3 molecules which relate to the following markets:-

- A non steroidal anti-inflammatory drug: Est. $5 billion market size
- A bronchodilator/chronic respiratory drug: Est. $100 million market size
- A non-opiate analgesic for localised pain relief: Est. $3 billion market size

Work continues.
Future of MVP
New manufacturing technology

We have successfully invented a process to manufacture a small molecule pharmaceutical where the raw material is usually purchased at Reaction Step 4.

We are investigating ways we can make the raw material at Reaction Step 4 using our technology (i.e. Reaction Step 1 to 4).

If so, the result could be that this small molecule will be manufactured at a fraction of the price the world currently makes it at.
Future of MVP
Intellectual Property

MVP is protecting its future by generating intellectual property from its manufacturing technology and delivery devices.

MVP has filed and is managing the following patents and trademarks:
• 6 Penthrox Inhaler patents;
• 1 manufacturing patent; and
• numerous trademark filings to mirror global growth.

MVP is also generating significant “Data Exclusivity” rights from its successful regulatory approvals around the world.

Note: “Data Exclusivity” works like a patent and protects the product in market from competition but usually for a shorter period of time.
MVP’s ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months+ we expect to:

1. obtain approval to sell Penthrox in 37 countries throughout Europe and in a number of countries outside the EU. We expect to make first sales during H2FY18 into many of these new countries. However we expect more material sales growth to commence during FY19 and beyond as the various approvals at hospital level are obtained and the use of Penthrox becomes “main stream”.

2. conclude additional distribution partnership for new countries;

3. commence and progress work on gathering the clinical data needed to submit a “New Drug Application” to the Food & Drug Administration in the USA, and extend the ‘indications for use’ for Penthrox; and

4. continue work to develop a new manufacturing process for small molecule pharmaceuticals and create significant intellectual property.
Respiratory and Medical Devices
Sales of Respiratory Devices across the world grew 50%
Sales of Respiratory Devices in the USA grew 353%
We now have almost 11,000 pharmacies available to sell our product across the USA
Sales of Respiratory Devices in Europe grew 32%
Sales of Breath-A-Tech in Australia grew 182%
Sales of Medical Devices globally (including VET) grew 45%
Respiratory Devices
Sold in 20 countries
We have access to 11,000 pharmacies in the USA
We are core range for Walmart, Sam’s, Kmart and others
There are 67,000 pharmacies in the USA
The response to our product offering in the USA has been excellent
We are working on additional pharmacy chain deals
We are now adding focus to GPO Hospital contracts
We expect excellent sales growth to be generated from the USA
MVP is protecting its future by generating intellectual property from its new range of respiratory devices.

MVP has filed a number of global patents.

MVP has filed international Trade Marks and Registered Designs in more than 20 countries.
MVP’s ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 20 countries.

Over the next 12 months we expect to:

1. obtain additional partnership deals in the USA and deliver sales growth;
2. obtain additional partnership deals in other countries around the world;
3. consolidate our position as the largest supplier of Respiratory Devices in Australia;
4. introduce new products; and
5. continue to drive down costs and increase the range and quality of our products.
MVP Corporate
Financial Summary

During the year MVP:
• Delivered gross sales of $18.9m up 22%
• Delivered Net Profit after tax of $1.82million up 16%
• Incurred $550K of “one off” expenses
• Reinvested profits, upfronts and milestones back into the business to facilitate global growth
• Paid 4 cent fully franked dividends
Financial Summary

MVP:

- Recently secured a Debt Funding facility of $11m which will be used to fund future development projects
- Received $7.3m in upfront and milestone payments from partners
- Invested:
  - $4.3m into the new manufacturing facility,
  - $4.3m into clinical trials and Penthrox regulatory approvals
  - $1.2m in dividends
MDI Investor Dashboard (ASX: MVP)

Historical Stock Chart (3yr)

Current Stock Price

5.14  $0.010 (0.19%)
16 Aug, 3:26pm

Day High  5.150
Day Low   5.090
Open      5.150
Prev. Close 5.150
Avg. Volume 13,332

52 Wk. High 5.990 (16 Aug 2016)
52 Wk. Low  4.120 (6 Dec 2016)
Mkt. Cap   300.18 (M)
MVP Corporate Overview

David Williams
Non-Executive Chairman
The Managing Director of Kidder Williams Ltd, with 32 years experience in investment banking.

Dr Harry Oxer
Non-Executive Director
A Medical Consultant to MVP and St John Ambulance in Western Australia.

Leon Hoare
Non-Executive Director
Recent Managing Director of Smith & Nephew in Australia and New Zealand.

Max Johnston
Non-Executive Director
Former MD of J&J Pacific. Non-Executive Director of Polynovo Limited and Former Chairman of Probiotec Limited.

Allan McCallum
Non-Executive Director
Over 20 years public companies experience including an ASX 50 company.

Phillip Powell
Non-Executive Director
A Chartered Accountant and has an extensive finance background.

John Sharman
Chief Executive Officer

Mark Edwards
Group Financial Controller & Company Secretary

Glenn Gilbert
Head, Sales & Marketing

Scott Courtney
Director of Operations & Research

Maggie Oh
Director of Scientific Affairs

Jake Golding
Quality Assurance & Validation Manager
MVP Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)

Product innovation
(world’s best manufacturing processes and delivery devices resulting in significant IP)

Regulatory Approval and new markets

New Business Partners

Clinical trials
(Commercial clinical studies to support marketing and product development)
Contact Details

HEAD OFFICE

4 Caribbean Drive
Scoresby, Victoria, Australia, 3179

Tel: +61 3 9547 1888
Fax: +61 3 9547 0262
Web: www.medicaldev.com